08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Japan Tobacco, Leo Pharma deal

Japan Tobacco granted Leo exclusive, ex-Japan rights to develop and commercialize JTE-052 for topical use to treat dermatological indications. The oral JAK kinase (JAK) inhibitor is in Phase I trials to treat inflammatory skin conditions....